8-K current report · filed Nov 12, 2026

Praxis Precision Medicines, Inc. (PRAX) 8-K Current Report: November 12, 2026

Item 7.01Item 8.01Item EX-99.1PRAX overview

Short answer

Praxis Precision Medicines, Inc. (PRAX) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Investor Day presentation disclosed on November 12, 2026, covering Praxis Precision Medicines’ investor-focused updates.

Praxis Precision Medicines, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Investor Day presentation disclosed on November 12, 2026, covering Praxis Precision Medicines’ investor-focused updates
  • Presentation available at investors.praxismedicines.com and furnished as Exhibit 99.1
  • Investors should review Exhibit 99.1 for pipeline, clinical, corporate and financial information not included in the 8-K text

Item 8.01 · Other Events

  • Ulixacaltamide targets about 2 million treatment-seeking U.S. ET patients within an estimated 9 million prevalence population
  • Essential3 endpoint sensitivity analyses matched the primary result, supporting the NDA’s evidentiary consistency
  • Long-term ulixacaltamide data showed improving ADL response after approximately 95 weeks, strengthening chronic-use rationale
  • Relutrigine produced an 86% seizure reduction from baseline through 18 months in SCN2A/SCN8A-DEEs extension data
  • Pipeline expansion adds 2027 studies in Parkinson’s, restless legs syndrome and autism, plus PRAX-215 pain readout expected in 2027

Item EX-99.1 · Exhibit EX-99.1

  • Investor Day outlines two planned launches: relutrigine on December 27, 2026 and ulixacaltamide on January 29, 2027
  • Ulixacaltamide PDUFA date January 29, 2027, creating a near-term regulatory catalyst in essential tremor
  • ESSENTIAL3 showed significant functional improvement, including p < 0.0001 in Study 1 and 55% response maintenance versus 33% placebo
  • Pipeline spans epilepsy, movement disorders, neurodevelopment and pain, supporting Praxis’ strategy to build a neurology-focused commercial platform
  • Management cites $20B+ peak sales guidance including pipeline, while consensus estimates ulixacaltamide sales of $10.0B and relutrigine sales of $5.0B

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Praxis Precision Medicines, Inc. 8-K filings

Get the next PRAX 8-K as it lands

Follow PRAX for push alerts, or ask the research agent what this filing means.